Evaluating a new imaging technology for cancer treatment
Evaluation of Image Quality From an On-Couch, Cone Beam Computed Tomography (CBCT) Radiation Treatment System for Image Guidance and Treatment Adaptation
This study is testing a new imaging technology to see if it can improve the accuracy of radiation treatment for people with different types of cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Varian, a Siemens Healthineers Company Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06576908 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the image quality and usability of a high-performance on-couch CBCT imaging technology called HyperSight in patients undergoing radiation treatment for various types of cancer. It is a prospective, single-arm, single-site study conducted at the Princess Margaret Cancer Centre. Participants will receive radiation therapy using a Varian TrueBeam treatment system, and the study will generate data on the effectiveness of this imaging technology in enhancing treatment precision.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of primary or metastatic cancer who are scheduled to receive radiation therapy.
Not a fit: Patients who are pregnant or part of a vulnerable population may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of radiation therapy for cancer patients, leading to better treatment outcomes.
How similar studies have performed: While this specific imaging technology is novel, similar studies have shown that advanced imaging techniques can enhance treatment precision in radiation therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient age is ≥ 18 years old. * Patient has a diagnosis of primary or metastatic cancer, including but not limited to tumors arising from or involving the head/neck, lungs, liver, pancreas, prostate, urinary bladder, rectum, cervix or uterus. * A previous (standard-of-care) decision was made to treat the patient with radiation therapy using a Varian TrueBeam treatment system. * A previous (standard-of-care) decision was made to treat the patient with a radiation dose of at least 20 Gy in at least 5 fractions, one fraction per day on consecutive days, Monday to Friday. * Patient is willing and able to provide informed consent to participate in the study. Exclusion Criteria: * Patient is pregnant or has plans for pregnancy during the period of treatment. * Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Centre (University Health Network) — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Sean Davidson
- Email: sean.davidson@varian.com
- Phone: 437-991-8294
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.